Literature DB >> 22315135

The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population.

Patricia Rodrigues1, Jessica Furriol, Eduardo Tormo, Sandra Ballester, Ana Lluch, Pilar Eroles.   

Abstract

Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis and thereby involved in the development and progression of solid tumours. The association between polymorphisms of angiogenesis pathway genes and risk of breast cancer (BC) has been widely studied, but the results are not conclusive. This information is especially limited in Spanish women, so we decided to conduct a case-control study. Here, we selected four commonly studied polymorphisms in VEGF, rs3025039 (known as +936 C/T), rs1109324, rs154765 and rs833052, one polymorphism at the promoter of the VEGFR1 (-710 C/T) and another in the FGF2, rs1449683, gene to explore their association with BC susceptibility. Genotyping was performed by TaqMan SNP assays and polymerase chain reaction-restriction fragment length polymorphis (PCR-RFLP) on 453 patients and 461 controls in a population from Valencia (Spain). We observed that women carriers of +936 CT + TT VEGF genotypes have a protective effect concerning this disease (p = 0.014; OR 0.67, 95% CI 0.48-0.92) in the global group of patients. The haplotype TGAC of VEGF (rs3025039, rs1109324, rs154764 and rs833052) shows a reduction of the risk to develop BC (p = 3e-04; OR 0.48, 95% CI 0.32-0.72). Furthermore, we found that carriers of -710 CT + TT VEGFR1 genotypes have also a protective effect (p = 0.039; OR 0.55, 95% CI 0.31-0.98). When we stratified by groups of ages these associations were maintained. Our data report for the first time the association of the polymorphism -710 C/T VEGFR1 with BC. Additional experiments focused on VEGF-A, VEGFR1 and sVEGFR1 gene expression demonstrated that carriers of T allele at -710 C/T VEGFR1 genotype have higher levels of sVEGFR1/VEGF-A than the C/C genotype carriers. This was consistent with the hypothesis that this polymorphism may act as low penetrance risk factor. The data provided suggest that +936 C/T VEGF and -710 C/T VEGFR1 genotypes are likely important genetic markers of susceptibility to BC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315135     DOI: 10.1007/s10549-012-1980-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  27 in total

1.  Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.

Authors:  Patricia Rodrigues; Jessica Furriol; Eduardo Tormo; Sandra Ballester; Ana Lluch; Pilar Eroles
Journal:  Mol Cell Biochem       Date:  2013-04-06       Impact factor: 3.396

2.  Particle swarm optimization algorithm for analyzing SNP-SNP interaction of renin-angiotensin system genes against hypertension.

Authors:  Shyh-Jong Wu; Li-Yeh Chuang; Yu-Da Lin; Wen-Hsien Ho; Fu-Tien Chiang; Cheng-Hong Yang; Hsueh-Wei Chang
Journal:  Mol Biol Rep       Date:  2013-05-22       Impact factor: 2.316

3.  Haplotype-based association of Vascular Endothelial Growth Factor gene polymorphisms with urothelial bladder cancer risk in Tunisian population.

Authors:  Safa Ben Wafi; Amani Kallel; Mohamed Kacem Ben Fradj; Ahmed Sallemi; Sami Ben Rhouma; Meriam Ben Halima; Haifa Sanhaji; Yassine Nouira; Riadh Jemaa; Moncef Feki
Journal:  J Clin Lab Anal       Date:  2018-06-29       Impact factor: 2.352

4.  LRRC4 haplotypes are associated with pituitary adenoma in a Chinese population.

Authors:  Lan Xiao; Chaofeng Tu; Shuai Chen; Zhibin Yu; Qianqian Lei; Zeyou Wang; Gang Xu; Minghua Wu; Guiyuan Li
Journal:  Med Oncol       Date:  2014-02-23       Impact factor: 3.064

5.  Angiogenesis genes, dietary oxidative balance and breast cancer risk and progression: the Breast Cancer Health Disparities Study.

Authors:  Martha L Slattery; Esther M John; Gabriela Torres-Mejia; Abbie Lundgreen; Juan Pablo Lewinger; Mariana C Stern; Lisa Hines; Kathy B Baumgartner; Anna R Giuliano; Roger K Wolff
Journal:  Int J Cancer       Date:  2013-08-09       Impact factor: 7.396

6.  Association between vascular endothelial growth factor +936C/T polymorphism and breast cancer risk: a meta-analysis of 18 case-control studies.

Authors:  Danhui Huang; Jianhua Wu; Zhenya Sun; Senlin Huang; Yuzhao Zhang; Lingling Wang; Tao Zeng
Journal:  Int J Mol Epidemiol Genet       Date:  2016-09-30

7.  Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer.

Authors:  Hayra de Andrade Vieira-Monteiro; Daniely Regina Freitas-Alves; Marcelo Sobral-Leite; João Marcos de Azevedo Delou; Sheyla Maria Torres Goulart-Citrangulo; Camila Telles do Nascimento; Thales Nascimento E Castro; Sérgio Koifman; Jamila Alessandra Perini; Rosane Vianna-Jorge
Journal:  Cancer Biol Ther       Date:  2016-06-02       Impact factor: 4.742

8.  Association of -2549 insertion/deletion polymorphism of vascular endothelial growth factor with breast cancer in North Indian patients.

Authors:  Ruhi Kapahi; Mridu Manjari; Manjit Singh Uppal; Neeti Rajan Singh; Vasudha Sambyal; Kamlesh Guleria
Journal:  Genet Test Mol Biomarkers       Date:  2013-02-07

9.  Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study.

Authors:  Martha L Slattery; Esther M John; Mariana C Stern; Jennifer Herrick; Abbie Lundgreen; Anna R Giuliano; Lisa Hines; Kathy B Baumgartner; Gabriela Torres-Mejia; Roger K Wolff
Journal:  Breast Cancer Res Treat       Date:  2013-08-03       Impact factor: 4.872

10.  Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk.

Authors:  Yanfeng Yang; Xuepei Zhang; Dongkui Song; Jinxing Wei
Journal:  Mol Clin Oncol       Date:  2014-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.